Jan Beyer‐Westendorf

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Stuart J. Connolly, Mark Crowther, John W. Eikelboom et al. · New England Journal of Medicine · 2019 · 920 citations · Full text

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

Stuart J. Connolly, Truman J. Milling, John W. Eikelboom et al. · New England Journal of Medicine · 2016 · 772 citations · Full text

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Jeffrey I. Weitz, Anthonie W.A. Lensing, Martin H. Prins et al. · New England Journal of Medicine · 2017 · 750 citations · Full text

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

Christoph Male, Anthonie W.A. Lensing, Joseph S. Palumbo et al. · The Lancet Haematology · 2019 · 294 citations · Full text

Pulmonary Embolism, Thrombosis, Venous Thrombosis +9

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials

Martin H. Prins, Anthonie W.A. Lensing, Tim Brighton et al. · The Lancet Haematology · 2014 · 282 citations

Pooled Subgroup Analysis, Thrombosis, Venous Thrombosis +14